Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Equity (2018 - 2025)

Crinetics Pharmaceuticals (CRNX) has 8 years of Return on Equity data on record, last reported at 0.45% in Q4 2025.

  • For Q4 2025, Return on Equity fell 17.0% year-over-year to 0.45%; the TTM value through Dec 2025 reached 0.45%, down 17.0%, while the annual FY2025 figure was 0.4%, 8.0% down from the prior year.
  • Return on Equity reached 0.45% in Q4 2025 per CRNX's latest filing, down from 0.38% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.25% in Q1 2025 and bottomed at 0.69% in Q2 2023.
  • Average Return on Equity over 5 years is 0.42%, with a median of 0.4% recorded in 2022.
  • Peak YoY movement for Return on Equity: fell -30bps in 2023, then soared 39bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.41% in 2021, then dropped by -20bps to 0.49% in 2022, then increased by 21bps to 0.38% in 2023, then rose by 28bps to 0.28% in 2024, then tumbled by -63bps to 0.45% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.45% in Q4 2025, 0.38% in Q3 2025, and 0.3% in Q2 2025.